Developed through a collaboration between the University of Vienna and the European Molecular Biology Laboratory (EMBL), SweetBac™ is the world’s first baculovirus that produces humanized glycosylation patterns on recombinantly expressed proteins. SweetBac™ provides unique advantages over existing baculovirus expression systems for i) production of targets for drug discovery and assay development ii) antibody development against membrane proteins like GPCRs and ion channels, and iii) manufacturing of biologics in insect cells with humanized glycosylation patterns.